Frailty, Sarcopenia, and Malnutrition in Cirrhotic Patients

Aby, Elizabeth S.; Saab, Sammy

doi:10.1016/j.cld.2019.06.001

Cited by 22 publications

(24 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In individuals with chronic liver damages (CLDs), metabolic or nutritional disorders including protein-energy-malnutrition or muscle abnormalities are frequently observed, which can be related to falls, poor quality of life or poor prognosis (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11). When the liver function deteriorates, the ability to detoxify harmful substances such as ammonia can decrease.…”

Section: Abstract Background/aim: To Elucidate the Influence Of Calfmentioning

confidence: 99%

Calf Circumference as a Useful Predictor of Sarcopenia in Patients With Liver Diseases

Nishikawa

Enomoto

Iwata

et al. 2020

In Vivo

View full text Add to dashboard Cite

Section: Abstract Background/aim: To Elucidate the Influence Of Calfmentioning

confidence: 99%

Calf Circumference as a Useful Predictor of Sarcopenia in Patients With Liver Diseases

Nishikawa

Enomoto

Iwata

et al. 2020

In Vivo

View full text Add to dashboard Cite

“…Skeletal muscle is crucial for mobility, regulating the metabolism of glucose and fats, cardiopulmonary function, immune function, cytokine balance, and activities of daily life [1,2]. Sarcopenia, as defined by decreased muscle strength and a muscle mass decline, is a common syndrome in patients with chronic liver diseases (CLDs) due to the disease burden itself (i.e., secondary sarcopenia) [3][4][5][6]. Physical activity and quality of life (QOL) are also likely to be impaired in CLD patients with sarcopenia due to skeletal muscle mass loss and muscle contractile dysfunction [7,8].…”

Section: Introductionmentioning

confidence: 99%

Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases

et al. 2020

View full text Add to dashboard Cite

Here we sought to clarify the prognostic impact of sarcopenia-related markers (grip strength (GS), muscle mass using bioimpedance analysis and patient quality of life as assessed by the 36-Item Short-Form Health Survey (SF36)) in patients with chronic liver diseases (CLDs, n = 411; 160 liver cirrhosis patients; median age, 64 years) on the incidence of composite hepatic events (CHEs). A GS decrease was defined as <26 kg in men and <18 kg in women, while a skeletal muscle mass index (SMI) decrease was defined as <7.0 kg/m2 in men and <5.7 kg/m2 in women based on the current guidelines. The physical and metal component summary scores on the SF36 were also included into the analysis. Sixty-two patients (15.1%) had the first incidence of CHEs. The three-year cumulative incidence rates of CHEs in patients with GS decrease or non-decrease were 24.51% and 12.44% (p = 0.0057). The three-year cumulative incidence rates of CHEs in patients with an SMI decrease or non-decrease were 19.65% and 12.99% (p = 0.0982). Multivariate analysis revealed that GS decrease (p = 0.0350) and prothrombin time (p = 0.0293) were significantly associated with the incidence of CHEs. In conclusion, GS can be an independent predictor for CHE development in patients with CLDs.

show abstract

“…Because sarcopenia, as defined by muscle mass decline and muscle strength decline in patients with chronic liver diseases (CLDs), can be associated with falls, decreased quality of life, or poor prognosis, it has gained much interest among clinicians these days [1][2][3][4][5][6][7]. Sarcopenia, especially, can occur frequently in patients with liver cirrhosis (LC), and it can be a risk factor for the development of hepatic encephalopathy in LC patients [8,9].…”

Section: Introductionmentioning

confidence: 99%

Walking Speed: Japanese Data in Chronic Liver Diseases

Nishikawa

Enomoto

Iwata

et al. 2020

JCM

View full text Add to dashboard Cite

We aim to clarify the impact of walking speed (WS) and analyze factors linked to WS decline in patients with chronic liver diseases (CLDs, 165 males and 191 females, 137 liver cirrhosis patients). The WS decline is defined as <0.8 m/second (m/s), referring to the guidelines. The median (range) WS was 1.3 m/s (0.2–2.02 m/s). There were 17 patients with WS < 0.8 m/s (4.8%). The WS value was significantly correlated with the handgrip strength value both in males (r2 = 0.252, p < 0.0001) and females (r2 = 0.256, p < 0.0001). In the multivariate analysis of factors associated with WS decline, only the extracellular water (ECW) to total body water (TBW) ratio using bioimpedance analysis was an independent predictor (p = 0.0398). Extracellular fluid excess was categorized as follows: normal condition (ECW to TBW ratio < 0.390), mild overhydrated condition (ECW to TBW ratio 0.390–0.399), and moderate to severe overhydrated condition (ECW to TBW ratio ≥ 0.400). The WS value was well stratified according to the ECW to TBW ratio (normal vs. mild, p = 0.0001; mild vs. moderate to severe, p < 0.0001; normal vs. moderate to severe, p < 0.0001; overall p-value < 0.0001). In conclusion, the ECW to TBW ratio can be closely linked to WS decline in CLD patients.

show abstract

Frailty, Sarcopenia, and Malnutrition in Cirrhotic Patients

Cited by 22 publications

References 113 publications

Calf Circumference as a Useful Predictor of Sarcopenia in Patients With Liver Diseases

Calf Circumference as a Useful Predictor of Sarcopenia in Patients With Liver Diseases

Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases

Walking Speed: Japanese Data in Chronic Liver Diseases

Contact Info

Product

Resources

About